Nimotuzumab in Combination With Paclitaxel Liposome and Carboplatin (TP Regimen) for the Advanced NSCLC Patients
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Nimotuzumab (hR3) is an IgG1 humanized monoclonal antibody that recognized an epitope located
in the extra cellular domain of the human epidermal growth factor receptor (EGFR). Clinical
efficacy has been shown in adults with head and neck cancer. This study assesses the efficacy
and safety of the combination of Nimotuzumab administered concomitantly with chemotherapy in
patients with NSCLC. This is a randomized, muti-center sites trial of this treatment.
Phase:
N/A
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital